Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | DS-1055a |
| Synonyms | |
| Therapy Description |
DS-1055a is an afucosylated monoclonal antibody that targets LRRC32 (GARP), which potentially increases anti-tumor immune response and decreases tumor growth (PMID: 34235533). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| DS-1055a | DS1055a|DS 1055a | DS-1055a is an afucosylated monoclonal antibody that targets LRRC32 (GARP), which potentially increases anti-tumor immune response and decreases tumor growth (PMID: 34235533). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04419532 | Phase I | DS-1055a | A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors | Active, not recruiting | USA | CAN | 1 |